Aerie Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, AERI, Aerie Pharmaceuticals Inc, priceseries

Aerie Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
7.90
Close
7.77
High
8.23
Low
7.72
Previous Close
7.96
Daily Price Gain
-0.19
YTD High
8.62
YTD High Date
Mar 2, 2022
YTD Low
5.46
YTD Low Date
Feb 24, 2022
YTD Price Change
0.28
YTD Gain
3.74%
52 Week High
21.30
52 Week High Date
Mar 15, 2021
52 Week Low
5.46
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-11.65
52 Week Gain
-59.99%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Oct 10. 2017
55.35
Oct 26. 2017
61.69
12 Trading Days
11.45%
Link
LONG
May 31. 2018
51.30
Jul 2. 2018
65.55
22 Trading Days
27.79%
Link
LONG
Jan 9. 2019
39.84
Feb 6. 2019
45.18
19 Trading Days
13.39%
Link
LONG
Dec 3. 2019
19.08
Dec 30. 2019
23.00
18 Trading Days
20.53%
Link
LONG
Apr 8. 2020
13.40
Apr 21. 2020
14.08
8 Trading Days
5.04%
Link
LONG
Jan 19. 2021
15.07
Feb 1. 2021
16.98
9 Trading Days
12.70%
Link
LONG
Jun 16. 2021
16.12
Jun 29. 2021
17.12
9 Trading Days
6.19%
Link
LONG
Nov 1. 2021
11.02
Nov 12. 2021
11.95
9 Trading Days
8.42%
Link
Company Information
Stock Symbol
AERI
Exchange
NasdaqGM
Company URL
http://www.aeriepharma.com
Company Phone
919-313-9650
CEO
Vicente J. Anido
Headquarters
North Carolina
Business Address
7020 KIT CREEK ROAD, SUITE 270, RESEARCH TRIANGLE PARK, NC 27709
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Major
CIK
0001337553
About

Aerie Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which is focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. It product candidates are Rhopressa and Roclatan. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem and Eric J. Toone on June 22, 2005 and is headquartered in Irvine, CA.

Description

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. was founded in 2005 and is based in Irvine, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading